PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors

Sarah Croessmann, Jonathan H. Sheehan, Kyung min Lee, Gregory Sliwoski, Jie He, Rebecca Nagy, David Riddle, Ingrid A. Mayer, Justin M. Balko, Richard Lanman, Vincent A. Miller, Lewis C. Cantley, Jens Meiler, Carlos L. Arteaga

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: We describe herein a novel P447_L455 deletion in the C2 domain of PIK3CA in a patient with an ERþ breast cancer with an excellent response to the PI3Ka inhibitor alpelisib. Although PIK3CA deletions are relatively rare, a significant portion of deletions cluster within amino acids 446–460 of the C2 domain, suggesting these residues are critical for p110a function. Experimental Design: A computational structural model of PIK3CAdelP447-L455 in complex with the p85 regulatory subunit and MCF10A cells expressing PIK3CAdelP447-L455 and PIK3CAH450_P458del were used to understand the phenotype of C2 domain deletions. Results: Computational modeling revealed specific favorable inter-residue contacts that would be lost as a result of the deletion, predicting a significant decrease in binding energy. Coimmunoprecipitation experiments showed reduced binding of the C2 deletion mutants with p85 compared with wild-type p110a. The MCF10A cells expressing PIK3CA C2 deletions exhibited growth factor–independent growth, an invasive phenotype, and higher phosphorylation of AKT, ERK, and S6 compared with parental MCF10A cells. All these changes were ablated by alpelisib treatment. Conclusions: C2 domain deletions in PIK3CA generate PI3K dependence and should be considered biomarkers of sensitivity to PI3K inhibitors.

Original languageEnglish (US)
Pages (from-to)1426-1435
Number of pages10
JournalClinical Cancer Research
Volume24
Issue number6
DOIs
StatePublished - Mar 15 2018

Fingerprint

1-Phosphatidylinositol 4-Kinase
Oncogenes
Phenotype
S 6
Structural Models
Growth
Research Design
Biomarkers
Phosphorylation
Breast Neoplasms
Amino Acids
C2 Domains
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors. / Croessmann, Sarah; Sheehan, Jonathan H.; Lee, Kyung min; Sliwoski, Gregory; He, Jie; Nagy, Rebecca; Riddle, David; Mayer, Ingrid A.; Balko, Justin M.; Lanman, Richard; Miller, Vincent A.; Cantley, Lewis C.; Meiler, Jens; Arteaga, Carlos L.

In: Clinical Cancer Research, Vol. 24, No. 6, 15.03.2018, p. 1426-1435.

Research output: Contribution to journalArticle

Croessmann, S, Sheehan, JH, Lee, KM, Sliwoski, G, He, J, Nagy, R, Riddle, D, Mayer, IA, Balko, JM, Lanman, R, Miller, VA, Cantley, LC, Meiler, J & Arteaga, CL 2018, 'PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors', Clinical Cancer Research, vol. 24, no. 6, pp. 1426-1435. https://doi.org/10.1158/1078-0432.CCR-17-2141
Croessmann, Sarah ; Sheehan, Jonathan H. ; Lee, Kyung min ; Sliwoski, Gregory ; He, Jie ; Nagy, Rebecca ; Riddle, David ; Mayer, Ingrid A. ; Balko, Justin M. ; Lanman, Richard ; Miller, Vincent A. ; Cantley, Lewis C. ; Meiler, Jens ; Arteaga, Carlos L. / PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 6. pp. 1426-1435.
@article{2a7e7d5d444140a1ad09e31454145155,
title = "PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors",
abstract = "Purpose: We describe herein a novel P447_L455 deletion in the C2 domain of PIK3CA in a patient with an ER{\th} breast cancer with an excellent response to the PI3Ka inhibitor alpelisib. Although PIK3CA deletions are relatively rare, a significant portion of deletions cluster within amino acids 446–460 of the C2 domain, suggesting these residues are critical for p110a function. Experimental Design: A computational structural model of PIK3CAdelP447-L455 in complex with the p85 regulatory subunit and MCF10A cells expressing PIK3CAdelP447-L455 and PIK3CAH450_P458del were used to understand the phenotype of C2 domain deletions. Results: Computational modeling revealed specific favorable inter-residue contacts that would be lost as a result of the deletion, predicting a significant decrease in binding energy. Coimmunoprecipitation experiments showed reduced binding of the C2 deletion mutants with p85 compared with wild-type p110a. The MCF10A cells expressing PIK3CA C2 deletions exhibited growth factor–independent growth, an invasive phenotype, and higher phosphorylation of AKT, ERK, and S6 compared with parental MCF10A cells. All these changes were ablated by alpelisib treatment. Conclusions: C2 domain deletions in PIK3CA generate PI3K dependence and should be considered biomarkers of sensitivity to PI3K inhibitors.",
author = "Sarah Croessmann and Sheehan, {Jonathan H.} and Lee, {Kyung min} and Gregory Sliwoski and Jie He and Rebecca Nagy and David Riddle and Mayer, {Ingrid A.} and Balko, {Justin M.} and Richard Lanman and Miller, {Vincent A.} and Cantley, {Lewis C.} and Jens Meiler and Arteaga, {Carlos L.}",
year = "2018",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-17-2141",
language = "English (US)",
volume = "24",
pages = "1426--1435",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors

AU - Croessmann, Sarah

AU - Sheehan, Jonathan H.

AU - Lee, Kyung min

AU - Sliwoski, Gregory

AU - He, Jie

AU - Nagy, Rebecca

AU - Riddle, David

AU - Mayer, Ingrid A.

AU - Balko, Justin M.

AU - Lanman, Richard

AU - Miller, Vincent A.

AU - Cantley, Lewis C.

AU - Meiler, Jens

AU - Arteaga, Carlos L.

PY - 2018/3/15

Y1 - 2018/3/15

N2 - Purpose: We describe herein a novel P447_L455 deletion in the C2 domain of PIK3CA in a patient with an ERþ breast cancer with an excellent response to the PI3Ka inhibitor alpelisib. Although PIK3CA deletions are relatively rare, a significant portion of deletions cluster within amino acids 446–460 of the C2 domain, suggesting these residues are critical for p110a function. Experimental Design: A computational structural model of PIK3CAdelP447-L455 in complex with the p85 regulatory subunit and MCF10A cells expressing PIK3CAdelP447-L455 and PIK3CAH450_P458del were used to understand the phenotype of C2 domain deletions. Results: Computational modeling revealed specific favorable inter-residue contacts that would be lost as a result of the deletion, predicting a significant decrease in binding energy. Coimmunoprecipitation experiments showed reduced binding of the C2 deletion mutants with p85 compared with wild-type p110a. The MCF10A cells expressing PIK3CA C2 deletions exhibited growth factor–independent growth, an invasive phenotype, and higher phosphorylation of AKT, ERK, and S6 compared with parental MCF10A cells. All these changes were ablated by alpelisib treatment. Conclusions: C2 domain deletions in PIK3CA generate PI3K dependence and should be considered biomarkers of sensitivity to PI3K inhibitors.

AB - Purpose: We describe herein a novel P447_L455 deletion in the C2 domain of PIK3CA in a patient with an ERþ breast cancer with an excellent response to the PI3Ka inhibitor alpelisib. Although PIK3CA deletions are relatively rare, a significant portion of deletions cluster within amino acids 446–460 of the C2 domain, suggesting these residues are critical for p110a function. Experimental Design: A computational structural model of PIK3CAdelP447-L455 in complex with the p85 regulatory subunit and MCF10A cells expressing PIK3CAdelP447-L455 and PIK3CAH450_P458del were used to understand the phenotype of C2 domain deletions. Results: Computational modeling revealed specific favorable inter-residue contacts that would be lost as a result of the deletion, predicting a significant decrease in binding energy. Coimmunoprecipitation experiments showed reduced binding of the C2 deletion mutants with p85 compared with wild-type p110a. The MCF10A cells expressing PIK3CA C2 deletions exhibited growth factor–independent growth, an invasive phenotype, and higher phosphorylation of AKT, ERK, and S6 compared with parental MCF10A cells. All these changes were ablated by alpelisib treatment. Conclusions: C2 domain deletions in PIK3CA generate PI3K dependence and should be considered biomarkers of sensitivity to PI3K inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85048124207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048124207&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-2141

DO - 10.1158/1078-0432.CCR-17-2141

M3 - Article

C2 - 29284706

AN - SCOPUS:85048124207

VL - 24

SP - 1426

EP - 1435

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -